Thuan le, MD
Infectious Disease · Murrieta, CANPI 1396842704
Payments from drug & device makers
Across 912 payments — averaging $165.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Melinta Therapeutics, LLC$40K
- AbbVie$20K
- Cumberland Pharmaceuticals, Inc.$18K
- Merck$17K
- Ferring Pharmaceuticals Inc.$12K
- GRT US Holding, Inc.$9K
- plus $33K from 26 others
What the payments were for
- Consulting fees$13,99910%
- Speaking & faculty fees$89,87863%
- Travel & lodging$9,4107%
- Food & beverage$27,61119%
- Education$1,6981%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Melinta Therapeutics, LLC | 77 | $40,236 |
| AbbVie(2 entities) | 106 | $19,749 |
| Cumberland Pharmaceuticals, Inc. | 55 | $18,449 |
| Merck | 105 | $17,063 |
| Ferring Pharmaceuticals Inc. | 24 | $12,203 |
| GRT US Holding, Inc. | 45 | $9,407 |
| Ferring Pharmaceuticals AS | 8 | $7,975 |
| Cipla USA Inc. | 20 | $7,099 |
| Insmed, Inc. | 73 | $4,875 |
| Viiv Healthcare Company | 175 | $4,192 |
| Astellas Pharma US Inc | 18 | $3,913 |
| Paratek Pharmaceuticals, Inc. | 62 | $1,314 |
| Theratechnologies Inc. | 34 | $859 |
| La Jolla Pharmaceutical Company | 25 | $715 |
| Smith+Nephew | 16 | $482 |
| Shionogi Inc | 14 | $366 |
| Gilead | 11 | $273 |
| Tetraphase Pharmaceuticals, Inc. | 9 | $220 |
| Abiomed | 3 | $193 |
| Octapharma USA, Inc. | 4 | $138 |
| Aimmune Therapeutics, Inc. | 2 | $126 |
| Amarin Pharma, Inc. | 1 | $112 |
| Averitas Pharma Inc. | 3 | $83 |
| Tactile Systems Technology Inc | 4 | $77 |
| Genentech, Inc. | 1 | $77 |
| Janssen Scientific Affairs, LLC | 1 | $77 |
| Nabriva Therapeutics, PLC | 3 | $64 |
| Pfizer | 3 | $59 |
| Johnson & Johnson(2 entities) | 4 | $57 |
| Sumitomo Pharma America, Inc. | 2 | $46 |
| Grifols USA, LLC | 2 | $39 |
| Mayne Pharma Commercial LLC | 2 | $33 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$150,570 in reported general payments places this provider in the 90th percentile of 856 infectious disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuzyraOmadacycline Tosylate | 48 | $480,870 |
| ArikayceAmikacin Liposomal/Neb.Accessr | 24 | $353,731 |
| JulucaDolutegravir/Rilpivirine | 39 | $241,869 |
| CabenuvaCabotegravir/Rilpivirine | 28 | $178,918 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 43 | $171,116 |
| Egrifta SvTesamorelin Acetate | 15 | $108,042 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 24 | $94,600 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 13 | $45,795 |
| Daptomycin | 20 | $32,903 |
| Meropenem | 13 | $5,717 |
| ErtapenemErtapenem Sodium | 15 | $5,611 |
| Cefepime Hcl | 25 | $4,114 |
| Vancomycin Hcl | 29 | $3,402 |
| Rifampin | 44 | $2,337 |
| Cephalexin | 18 | $2,309 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Paratek Pharmaceuticals, Inc.Nuzyra | $1,314 | $480,87048 claims |
| Viiv Healthcare CompanyJuluca, Cabenuva, Triumeq | $4,192 | $466,58280 claims |
| Insmed, Inc.Arikayce | $4,875 | $353,73124 claims |
| GileadBiktarvy, Genvoya | $273 | $265,71667 claims |
| Theratechnologies Inc.Egrifta Sv | $859 | $108,04215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 856 infectious disease providers in California.
Other infectious disease in Murrieta
- Peter RuaneLos Angeles$24.6M
- Raphael LandovitzLos Angeles$21.4M
- Philip RobinsonNewport Beach$4.9M
- Shawn HasslerSan Francisco$4.3M
- James McKinnellTorrance$4.3M
- Loren MillerTorrance$4.1M
- Jay GladsteinLos Angeles$4M
- Claire PomeroySacramento$3.8M
- Franco FelizartaBakersfield$3.5M
- Abhijit LimayeSan Francisco$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.